[go: up one dir, main page]

WO1997017977A1 - Compositions a application topique contenant une beta-cyclodextrine et un aminopolysaccharide - Google Patents

Compositions a application topique contenant une beta-cyclodextrine et un aminopolysaccharide Download PDF

Info

Publication number
WO1997017977A1
WO1997017977A1 PCT/GB1996/002768 GB9602768W WO9717977A1 WO 1997017977 A1 WO1997017977 A1 WO 1997017977A1 GB 9602768 W GB9602768 W GB 9602768W WO 9717977 A1 WO9717977 A1 WO 9717977A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclodextrin
composition
polysaccharide
amino
gel
Prior art date
Application number
PCT/GB1996/002768
Other languages
English (en)
Inventor
Selwyn Everest-Todd
Original Assignee
Everest-Todd Research & Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Everest-Todd Research & Development Limited filed Critical Everest-Todd Research & Development Limited
Priority to AU75787/96A priority Critical patent/AU719360B2/en
Priority to EP96938324A priority patent/EP0863761A1/fr
Priority to NZ322119A priority patent/NZ322119A/en
Publication of WO1997017977A1 publication Critical patent/WO1997017977A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Definitions

  • This invention relates to a treatment material applicable to wounds, injuries and a wide variety of diseases of the skin to reduce pain, inflammation and to increase the rate of healing of the affected area of the skin.
  • the chemistry of the inflammation processes of the skin has revealed the role of the enzyme phospholipase in the hydrolysis of lecithin and the release of free arachidonic acid.
  • Arachidonic acid is rapidly transformed to the leukotriene via lipoxygenase, thereby producing pain and inflammation.
  • this train of events can be halted by the topical application of clathrating agents in particular a composition for topical application for the relief of inflammation comprising an inert powder, or a gel, cream or dispersion or the like inert carrier, together with a ⁇ - cyclodextrin and an amino saccharide or polysaccharide.
  • clathrating agents in particular a composition for topical application for the relief of inflammation comprising an inert powder, or a gel, cream or dispersion or the like inert carrier, together with a ⁇ - cyclodextrin and an amino saccharide or polysaccharide.
  • Combinations of amino saccharides or polysaccharides and cyclodextrins according to the invention have been shown to be beneficial in the treatment of skin disorders such as eczema and psoriasis, and have unexpectedly been found to be more effective than either component alone.
  • a cross linked acrylic polymer in accordance with a preferred embodiment, a dry sterile dressing for the treatment wounds or injuries may be produced to which sterile water may be added immediately prior to application.
  • B-cyclodextrin is a cyclic polymer containing seven D-glucose units and has a doughnut-shaped molecular structure including an interior cavity which receive other molecules and form clathrate compounds therewith. While the efficacy of the invention does not depend on the correctness of the theory, it is believed that the cyclodextrin clathrates the arachidonic acid produced by the wound and thus effectively removes it and so prevents or reduces the pain and inflammation associated with it.
  • the amino saccharides and polysaccharides employed include chitin and products derived from chitin, for example by hydrolysis, to produce n-acetyl glucosamine which can then be de-acylated to give glucosamine or glucosamine hydrochloride.
  • Such compounds have analgesic or or anti-inflammatory properties and the efficacy thereof has been unexpectedly found to be enhanced when used with cyclodextrin an accordance with the invention.
  • glucosamine hydrochloride 50 Og of glucosamine hydrochloride 50. Og of dimethyl ⁇ . cyclodextrin made up to 1 litre with sterile water.
  • the mixture was mixed thoroughly and placed within a sachet made from bonded synthetic polymers measuring 10 x 15 cms.
  • the sealed sachet was maintained in a dry, sterile condition prior to use.
  • the mixture was mixed thoroughly prior to the addition of 1800ml of sterile water, added with constant agitation for a period of five (5) minutes.
  • the resultant gel was then preserved in sterile containers.
  • the ingredients were admixed and ground to a particle size of 50 microns.
  • the resultant powder was suitable for inclusion with synthetic polymers of incorporation with fabricated polymers.
  • Example I_ The lotion prepared as in Example I_ was applied to the affected tissue on patients suffering from psoriasis or eczema. All reported relief from pruritis within 10 minutes after application and regeneration of dermal tissue was observed on the fourth day.
  • the dressing was bandaged in place for twenty four hours. Relief from pain occurred within minutes and when the dressing was removed the healing process had commenced.
  • Example IV The powder produced as in Example IV was incorporated in the layer of fabric used to produce sanitary wear.
  • Candida albicans known as nappy rash
  • Other applications for the reduction of infection by this organism are related to age and sex.
  • the dimethyl ⁇ . cyclodextrin and ⁇ . cyclodextrin may be exchanged without detracting from the principle of the invention.
  • the amino polysaccharides as a group display similar characteristics from a therapeutic standpoint although the chemical and or physical properties may differ.
  • a colloidal suspension was prepared from a combination of chitin, chitosan and glucosamine having a particle size of less than 5 microns in an aqueous solution of /3-cyclodextrin in the following manner:
  • a non-woven polyester fabric was wetted with this suspension by short term immersion (1-2 seconds, nip rollers) then dried prior to forming into 10cm squares for use in surgical dressings as the contact surface with the perturbed tissue. When applied to lacerated tissue, relief from pain occured within minutes and the healing process was accelerated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pour une application topique, permettant d'atténuer la douleur ou une inflammation. La composition se présente sous la forme d'un gel, d'une crème, d'une dispersion ou d'une poudre inerte, comprenant un système clathrate contenant de la β-cyclodextrine et un aminopolysaccharide.
PCT/GB1996/002768 1995-11-15 1996-11-13 Compositions a application topique contenant une beta-cyclodextrine et un aminopolysaccharide WO1997017977A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU75787/96A AU719360B2 (en) 1995-11-15 1996-11-13 Topical compositions containing a beta-cyclodextrin and an amino polysaccharide
EP96938324A EP0863761A1 (fr) 1995-11-15 1996-11-13 Compositions a application topique contenant une beta-cyclodextrine et un aminopolysaccharide
NZ322119A NZ322119A (en) 1995-11-15 1996-11-13 Topical emulsion based upon a polysaccharide containing amino groups for treatment of skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9523335.9 1995-11-15
GB9523335A GB2307176A (en) 1995-11-15 1995-11-15 Anti-inflammatory clathrating agents for topical use

Publications (1)

Publication Number Publication Date
WO1997017977A1 true WO1997017977A1 (fr) 1997-05-22

Family

ID=10783900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/002768 WO1997017977A1 (fr) 1995-11-15 1996-11-13 Compositions a application topique contenant une beta-cyclodextrine et un aminopolysaccharide

Country Status (6)

Country Link
EP (1) EP0863761A1 (fr)
AU (1) AU719360B2 (fr)
CA (1) CA2237758A1 (fr)
GB (1) GB2307176A (fr)
NZ (1) NZ322119A (fr)
WO (1) WO1997017977A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736169A (en) * 1994-12-08 1998-04-07 Krauss-Maffei Ag Closing apparatus for multiple-mold injection-molding system
EP1127574A1 (fr) * 2000-02-22 2001-08-29 Food Industry Research and Development Institute L'utilisation des produits contenant du chitin pour inhiber la production de l'oxyde nitrique
US6653294B2 (en) 2000-02-29 2003-11-25 Food Industry Research & Development Institute Use of chitinous materials for inhibiting cellular nitric oxide production
USRE44733E1 (en) * 1999-11-29 2014-01-28 Merck Sharp & Dohme B.V. 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
EP2907518A1 (fr) * 2014-02-14 2015-08-19 SapioTec GmbH Analgésique
EP2913366A1 (fr) * 2014-02-28 2015-09-02 SapioTec GmbH Complexe à base d'anthocyanidine
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
US9949947B2 (en) 2012-12-11 2018-04-24 Sapiotec Gmbh Delphinidin for combating melanoma cells
WO2021100044A1 (fr) 2019-11-20 2021-05-27 Avgol Ltd. Procédés de fusion d'hôtes cyclodextrines avec une finition non-tissée pour former des tissés intelligents contenant divers agents bénéfiques et produits fabriqués à partir des procédés

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9626963D0 (en) * 1996-12-27 1997-02-12 Everest Todd Res & Dev Improved surgical dressings and method of preparation
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
DE10126396A1 (de) * 2001-05-31 2002-12-05 Beiersdorf Ag Verwendung von Glucosamin zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter und trockener Haut
LU91353B1 (de) * 2007-08-08 2009-02-09 Recipe Holding S A Glukosamin 1200mg, beutel
US10835584B2 (en) * 2016-06-17 2020-11-17 Nuvothera, Inc. Systems for treating dermal inflammatory conditions
IL284435B2 (en) 2019-01-03 2025-09-01 Cyclarity Therapeutics Inc Cyclodextrin dimers, their preparations and uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2647015A1 (fr) * 1989-05-17 1990-11-23 Cird Gel aqueux a base d'acide retinoique et son utilisation en medecine humaine et en cosmetique

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5423966B2 (fr) * 1972-11-11 1979-08-17
JPS5788123A (en) * 1980-11-20 1982-06-01 Kotsukusu Jiyaagen Beta-cyclodextrin as antiacne
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS61221120A (ja) * 1985-03-28 1986-10-01 Nitto Electric Ind Co Ltd 外用医薬部材
JPH0613448B2 (ja) * 1985-07-02 1994-02-23 三省製薬株式会社 皮膚弾力線維症予防剤
JPH0249711A (ja) * 1988-08-11 1990-02-20 Nikkei New Bijinesu Kk 新規基礎化粧用クリーム
GB8910069D0 (en) * 1989-05-03 1989-06-21 Janssen Pharmaceutica Nv Method of topically treating acne vulgaris
JPH04334321A (ja) * 1991-05-09 1992-11-20 Unitika Ltd 皮膚炎症予防剤
DE4220736A1 (de) * 1992-06-25 1994-01-05 Puetter Medice Chem Pharm Einschlußkomplexe aus polymerisierten Cyclodextrinen mit pharmazeutisch aktiven Wirkstoffen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2647015A1 (fr) * 1989-05-17 1990-11-23 Cird Gel aqueux a base d'acide retinoique et son utilisation en medecine humaine et en cosmetique

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736169A (en) * 1994-12-08 1998-04-07 Krauss-Maffei Ag Closing apparatus for multiple-mold injection-molding system
USRE44733E1 (en) * 1999-11-29 2014-01-28 Merck Sharp & Dohme B.V. 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
EP1127574A1 (fr) * 2000-02-22 2001-08-29 Food Industry Research and Development Institute L'utilisation des produits contenant du chitin pour inhiber la production de l'oxyde nitrique
US6653294B2 (en) 2000-02-29 2003-11-25 Food Industry Research & Development Institute Use of chitinous materials for inhibiting cellular nitric oxide production
US9925274B2 (en) 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
US9949947B2 (en) 2012-12-11 2018-04-24 Sapiotec Gmbh Delphinidin for combating melanoma cells
EP2907518A1 (fr) * 2014-02-14 2015-08-19 SapioTec GmbH Analgésique
WO2015121419A1 (fr) * 2014-02-14 2015-08-20 Sapiotec Gmbh Analgésique
EP2913366A1 (fr) * 2014-02-28 2015-09-02 SapioTec GmbH Complexe à base d'anthocyanidine
WO2015128437A1 (fr) * 2014-02-28 2015-09-03 Sapiotec Gmbh Complexe anthocyanidine
WO2021100044A1 (fr) 2019-11-20 2021-05-27 Avgol Ltd. Procédés de fusion d'hôtes cyclodextrines avec une finition non-tissée pour former des tissés intelligents contenant divers agents bénéfiques et produits fabriqués à partir des procédés

Also Published As

Publication number Publication date
GB9523335D0 (en) 1996-01-17
AU7578796A (en) 1997-06-05
CA2237758A1 (fr) 1997-05-22
GB2307176A (en) 1997-05-21
NZ322119A (en) 1998-09-24
EP0863761A1 (fr) 1998-09-16
AU719360B2 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
AU719360B2 (en) Topical compositions containing a beta-cyclodextrin and an amino polysaccharide
Lestari et al. A glimpse on the function of chitosan as a dental hemostatic agent
EP1483299B1 (fr) Derives de membranes cellulaires provenant de la biomasse et leur preparation
KR100343293B1 (ko) 친수성-흡습성중합체로부터의건조된하이드로겔
AU2011334627C1 (en) Glucan compositions
CA2712527C (fr) Gel de chitosane pour applications dermatologiques, procede d'obtention et d'utilisation de celui-ci
AU639163B2 (en) Methyl pyrrolidinone chitosan, production process and uses thereof
EP1948254B1 (fr) Composition d'hydrocolloïde
KR20200081403A (ko) 항균 초흡수성 조성물
KR101155884B1 (ko) 하이드로카르빌 설톤 화합물에 의해 화학적으로 변형된폴리아미노사카라이드
CA2520014C (fr) Procedes de production de corps faconnes poreux contenant de l'alginate
KR20200126078A (ko) 항균 및 항산화 기능의 키토산-만델산 고분자 전해질 복합체 및 그 수용액 조성물
JP5933178B2 (ja) キトサンカルボキシアルキルアミドのヒドロゲル、その調製方法、並びに、無水生成物、皮膚科組成物および美容用組成物
US11058712B2 (en) Film for topical application in the treatment of skin lesions and method of obtaining and applying same
WO2009032325A1 (fr) Objets profilés contenant un composant de phéromone humaine
JPH08245401A (ja) 皮膚保護剤
WO1990006124A1 (fr) Compositions pour le traitement de blessures a cicatrisation lente ou difficile
HK1100006B (en) Method for producing alginate-containing porous shaped bodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2237758

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2237758

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 322119

Country of ref document: NZ

Ref document number: 1996938324

Country of ref document: EP

NENP Non-entry into the national phase

Ref document number: 97518662

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996938324

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996938324

Country of ref document: EP